Molmed TK Ash: Long term assessment of TK clinical benefit at the 54th Annual Meeting

Milan , 10 December 2012 MolMed S.p.A. announces the presentation of the long term clinical benefit and safety data of its investigational cell-based therapy TK at the 54th Annual Meeting of the American Society of Hematology in Atlanta .

http://www.groundreport.com/Health_and_Science/Molmed-TK-ASH-Long-term-assessment-of-TK-clinical-/2950001